Citadel Advisors
AXSM icon

Citadel Advisors’s Axsome Therapeutics AXSM Stock Holding History

Citadel Advisors’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$38.3M Buy
156,300
+121,300
+347% +$26.3M ﹤0.01% 1836
2026
Q1 		$5.92M Sell
35,000
-44,800
-56% -$7.74M ﹤0.01% 4064
2025
Q4 		$14.6M Sell
79,800
-26,100
-25% -$3.64M ﹤0.01% 2737
2025
Q3 		$12.9M Buy
105,900
+3,400
+3% +$383K ﹤0.01% 2897
2025
Q2 		$10.7M Buy
102,500
+9,600
+10% +$1.02M ﹤0.01% 2934
2025
Q1 		$10.8M Sell
92,900
-30,600
-25% -$3.49M ﹤0.01% 2746
2024
Q4 		$10.4M Buy
123,500
+42,700
+53% +$3.93M ﹤0.01% 2931
2024
Q3 		$7.26M Buy
80,800
+6,200
+8% +$541K ﹤0.01% 3373
2024
Q2 		$6.01M Sell
74,600
-8,100
-10% -$600K ﹤0.01% 3466
2024
Q1 		$6.6M Sell
82,700
-8,000
-9% -$671K ﹤0.01% 3536
2023
Q4 		$7.22M Sell
90,700
-3,200
-3% -$214K ﹤0.01% 3277
2023
Q3 		$6.56M Sell
93,900
-49,700
-35% -$3.72M ﹤0.01% 3256
2023
Q2 		$10.3M Sell
143,600
-68,100
-32% -$5.02M ﹤0.01% 2636
2023
Q1 		$13.1M Sell
211,700
-477,900
-69% -$31.4M ﹤0.01% 2455
2022
Q4 		$53.2M Sell
689,600
-144,200
-17% -$8.62M 0.01% 1078
2022
Q3 		$37.2M Buy
833,800
+407,500
+96% +$20.4M 0.01% 1294
2022
Q2 		$16.3M Buy
426,300
+277,100
+186% +$8.76M ﹤0.01% 2068
2022
Q1 		$6.17M Sell
149,200
-130,700
-47% -$4.05M ﹤0.01% 3768
2021
Q4 		$10.6M Sell
279,900
-173,300
-38% -$6.38M ﹤0.01% 2987
2021
Q3 		$14.9M Buy
453,200
+255,200
+129% +$9.95M ﹤0.01% 2430
2021
Q2 		$13.4M Sell
198,000
-9,000
-4% -$540K ﹤0.01% 2636
2021
Q1 		$11.7M Buy
207,000
+44,000
+27% +$3.1M ﹤0.01% 2745
2020
Q4 		$13.3M Buy
163,000
+800
+0.5% +$59.8K ﹤0.01% 2272
2020
Q3 		$11.6M Buy
162,200
+36,100
+29% +$2.81M ﹤0.01% 2122
2020
Q2 		$10.4M Sell
126,100
-27,500
-18% -$2.12M ﹤0.01% 2168
2020
Q1 		$9.04M Sell
153,600
-15,400
-9% -$1.25M ﹤0.01% 1970
2019
Q4 		$17.5M Buy
169,000
+91,000
+117% +$3.68M 0.01% 1610
2019
Q3 		$1.58M Buy
78,000
+48,800
+167% +$1.25M ﹤0.01% 4849
2019
Q2 		$752K Sell
29,200
-27,800
-49% -$557K ﹤0.01% 6169
2019
Q1 		$811K Buy
+57,000
New +$529K ﹤0.01% 5970

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Citadel Advisors's AXSM Position: Q2 2026 in Review

Citadel Advisors reduced its Axsome Therapeutics (AXSM) stake by 9.1% in Q2 2026, selling an estimated $5.56M and leaving 255,878 shares worth $62.6M. The position accounts for 0.01% of the portfolio, ranked #1351.

Citadel Advisors first reported a position in AXSM in Q3 2016 and has held it in 32 quarters since. The position peaked at $91.3M in Q1 2024. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Citadel Advisors held 255,878 shares of Axsome Therapeutics worth $62.6M as of Q2 2026.
  • Citadel Advisors sold 25,625 Axsome Therapeutics shares in Q2 2026, an estimated $5.56M.
  • Axsome Therapeutics made up 0.01% of Citadel Advisors's portfolio in Q2 2026, its #1351 holding.
  • Citadel Advisors first reported a position in Axsome Therapeutics in Q3 2016 and has held it in 32 quarters since.
  • Citadel Advisors's Axsome Therapeutics position peaked at $91.3M in Q1 2024.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.